MGNX Valuation

MacroGenics Inc

Add to Watchlist

Advanced Chart

1.580

+0.02(1.282%)1D

Overview
Forecast
Valuation
Earnings

MGNX Relative Valuation

MGNX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MGNX is overvalued; if below, it's undervalued.

Historical Valuation

MacroGenics Inc (MGNX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.18 is considered Undervalued compared with the five-year average of -4.12. The fair price of MacroGenics Inc (MGNX) is between 6.48 to 16.47 according to relative valuation methord. Compared to the current price of 1.56 USD , MacroGenics Inc is Undervalued By 75.83%.

Relative Value

Fair Zone

6.48-16.47

Current Price：1.56

75.83%

Undervalued

-0.78

Trailing

Forward

0.00

EV/EBITDA

MacroGenics Inc. (MGNX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -3.62. The thresholds are as follows: Strongly Undervalued below -11.27, Undervalued between -11.27 and -7.45, Fairly Valued between 0.21 and -7.45, Overvalued between 0.21 and 4.03, and Strongly Overvalued above 4.03. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.10

EV/EBIT

MacroGenics Inc. (MGNX) has a current EV/EBIT of 0.10. The 5-year average EV/EBIT is -3.35. The thresholds are as follows: Strongly Undervalued below -9.48, Undervalued between -9.48 and -6.42, Fairly Valued between -0.29 and -6.42, Overvalued between -0.29 and 2.78, and Strongly Overvalued above 2.78. The current Forward EV/EBIT of 0.10 falls within the Overvalued range.

1.18

MacroGenics Inc. (MGNX) has a current PS of 1.18. The 5-year average PS is 5.90. The thresholds are as follows: Strongly Undervalued below -3.55, Undervalued between -3.55 and 1.17, Fairly Valued between 10.63 and 1.17, Overvalued between 10.63 and 15.35, and Strongly Overvalued above 15.35. The current Forward PS of 1.18 falls within the Historic Trend Line -Fairly Valued range.

-1.71

P/OCF

MacroGenics Inc. (MGNX) has a current P/OCF of -1.71. The 5-year average P/OCF is -6.25. The thresholds are as follows: Strongly Undervalued below -34.32, Undervalued between -34.32 and -20.28, Fairly Valued between 7.78 and -20.28, Overvalued between 7.78 and 21.82, and Strongly Overvalued above 21.82. The current Forward P/OCF of -1.71 falls within the Historic Trend Line -Fairly Valued range.

-0.68

P/FCF

MacroGenics Inc. (MGNX) has a current P/FCF of -0.68. The 5-year average P/FCF is -6.65. The thresholds are as follows: Strongly Undervalued below -18.16, Undervalued between -18.16 and -12.41, Fairly Valued between -0.90 and -12.41, Overvalued between -0.90 and 4.86, and Strongly Overvalued above 4.86. The current Forward P/FCF of -0.68 falls within the Overvalued range.

MacroGenics Inc (MGNX) has a current Price-to-Book (P/B) ratio of 1.23. Compared to its 3-year average P/B ratio of 2.96 , the current P/B ratio is approximately -58.57% higher. Relative to its 5-year average P/B ratio of 3.37, the current P/B ratio is about -63.51% higher. MacroGenics Inc (MGNX) has a Forward Free Cash Flow (FCF) yield of approximately -72.63%. Compared to its 3-year average FCF yield of -36.09%, the current FCF yield is approximately 101.26% lower. Relative to its 5-year average FCF yield of -30.01% , the current FCF yield is about 142.02% lower.

1.23

P/B

Median3y

2.96

Median5y

3.37

-72.63

FCF Yield

Median3y

-36.09

Median5y

-30.01

Competitors Valuation Multiple

The average P/S ratio for MGNX's competitors is 17.21, providing a benchmark for relative valuation. MacroGenics Inc Corp (MGNX) exhibits a P/S ratio of 1.18, which is -93.12% above the industry average. Given its robust revenue growth of 44.90%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Atlantic International Corp

Atossa Therapeutics Inc

Corbus Pharmaceuticals Holdings Inc

102.09

113.43M

Performance Decomposition

Market capitalization of MGNX decreased by 56.55% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 9.10M to 13.19M.

The secondary factor is the Margin Expansion, contributed -45.74%to the performance.

Overall, the performance of MGNX in the past 1 year is driven by Revenue Growth. Which is more sustainable.

44.90%

9.10M → 13.19M

Revenue Growth

-45.74%

-573.26 → -311.07

Margin Expansion

-55.71%

-3.91 → -1.73

P/E Change

-56.55%